Timely donor lymphocyte infusion (DLI) following the detection of impending molecular relapse may significantly improve ...

By: Dr. Amrit Kaur Kaler For patients diagnosed with blood cancers such as leukemia, lymphoma, and multiple myeloma, the ...

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat(R) KMT2A + MRD Assay and Software to its industry-leading ...

Cash-rich Cullinan Therapeutics stock: zipalertinib NDA in Q1 2026 plus CLN-978 and CLN-049 AML catalysts. Read here for more analysis.

DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human ...

This article is authored by Dr Amrit Kaur Kaler, consultant, molecular pathology, Kokilaben Dhirubhai Ambani Hospitals, ...

Amgen acquires Dark Blue Therapeutics to fight Acute Myeloid Leukemia. See how this $840M deal aims to deliver first-in-class ...

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway ...

QTX-2101, an oral arsenic trioxide, received FDA fast track designation for acute promyelocytic leukemia, aiming to simplify ...

QTX-2101 is an investigational, oral arsenic trioxide therapy that has not yet been approved by any regulatory authority. Its safety and efficacy are currently under evaluation. This press release ...